NEW APPROACH METHODOLOGIES (NAMS): ACCELERATING SAFER, SMARTER AND MORE HUMAN-RELEVANT INNOVATION IN DRUG AND CHEMICAL DEVELOPMENT
Tracks
SPEAKER'S ROOM 2: NICOLÁS ACHÚCARRO
| Wednesday, September 30, 2026 |
| 12:15 - 13:00 |
| SPEAKERS' CORNER 2: NICOLÁS ACHÚCARRO |
Overview
Sponsor: BeCytes Biotechnologies (A BioIVT Company)
Details
New Approach Methodologies (NAMs) are transforming the way drugs, medical products, and chemicals are evaluated by providing more predictive, human-relevant, and sustainable alternatives to traditional testing approaches. By integrating advanced in vitro models, computational tools, artificial intelligence, in silico toxicology, and innovative preclinical strategies, NAMs offer new opportunities to improve safety assessment, reduce development timelines, lower costs, and support regulatory decision-making.
This round table will bring together leading experts from industry and technology providers to explore the current state and future potential of NAMs across the life sciences sector. The discussion will examine how emerging methodologies are being implemented in research and development workflows, the scientific and regulatory challenges that remain, and the collaborative efforts needed to accelerate adoption Representatives from CMG MedDev will share their perspectives on the role of digital technologies, predictive modeling, advanced biological systems, and regulatory science in shaping the next generation of safety and efficacy assessment. The session will address key questions including: How can NAMs improve the predictivity and translational value of preclinical testing? What role do AI, computational toxicology, and in silico approaches play in modern risk assessment? How are regulators responding to the growing adoption of NAMs? What barriers are limiting broader implementation, and how can they be overcome? How can collaboration between biotechnology companies, technology developers, regulators, and investors accelerate the transition toward human-relevant innovation? Attendees will gain practical insights into the opportunities and challenges associated with NAMs, as well as a forward-looking view of how these technologies are reshaping drug development, chemical safety assessment, and the broader bioeconomy
This round table will bring together leading experts from industry and technology providers to explore the current state and future potential of NAMs across the life sciences sector. The discussion will examine how emerging methodologies are being implemented in research and development workflows, the scientific and regulatory challenges that remain, and the collaborative efforts needed to accelerate adoption Representatives from CMG MedDev will share their perspectives on the role of digital technologies, predictive modeling, advanced biological systems, and regulatory science in shaping the next generation of safety and efficacy assessment. The session will address key questions including: How can NAMs improve the predictivity and translational value of preclinical testing? What role do AI, computational toxicology, and in silico approaches play in modern risk assessment? How are regulators responding to the growing adoption of NAMs? What barriers are limiting broader implementation, and how can they be overcome? How can collaboration between biotechnology companies, technology developers, regulators, and investors accelerate the transition toward human-relevant innovation? Attendees will gain practical insights into the opportunities and challenges associated with NAMs, as well as a forward-looking view of how these technologies are reshaping drug development, chemical safety assessment, and the broader bioeconomy
Details
John Kendrick
Executive Director, NAMs and Emerging Technologies
Labcorp
.
Ms Carmen Martin
Ceo / Founder_senior Expert Consultant
CMG MEDDEV
.
Mr Simon Perera
BD Manager
ProtoQSAR SL
.
Secretariat AM Conferences & Meetings, S.L. - C/ Espronceda, 27 - 28003 Madrid Tel. ++34 918 33 74 33 email: biospain@biospain.com http://www.biospain.com/ |
